1. Scrip
  2. >>Business
  3. >>Financing

Tango Bypasses IPO Route With SPAC Merger

Cancer Firm Will Raise $353m, List On US Stock Market In Q3

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The cancer drug developer was planning to go public later this year, but its series B investor Boxer Capital proposed a merger with its special purpose acquisition corporation, BCTG Acquisition.

SPAC vs IPO blocks
Tango did not consider a SPAC merger until its investor Boxer Capital suggested a deal • Source: Alamy

Tango Therapeutics, Inc. will bring its cash balance to $553m later this year and become a publicly traded company in the US when it closes a merger with the special purpose acquisition corporation (SPAC) known as BCTG Acquisition Corp., which was sponsored by frequent biopharmaceutical company investor Boxer Capital. Tango will raise $353m through the deal announced on 14 April, including $167m held in trust by BCTG and $186m from a concurrent private investment in public equity (PIPE) financings.

SPACs, also known as blank check companies, launch initial public offerings to raise money that facilitates a merger with another...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.